◎ Sugi Atlas

Atlas / Disease / Acute cholecystitis

Acute cholecystitis

disease
On this page

Summary

Acute cholecystitis (MONDO:0043994) is a disease and 72 clinical trials. Top therapeutic interventions include indocyanine green acid form, amoxicillin, and ceftolozane. A subtype of acute cholangitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 72

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameacute cholecystitis
Mondo IDMONDO:0043994
MeSHD041881
ICD-10-CMK81.0
ICD-112071113448
NCITC35152
SNOMED CT65275009
UMLSC0149520
MedGen57682
Is cancer (heuristic)no

Also known as: acute cholecystitis

Disease family

This is a subtype of acute cholangitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › non-neoplastic bile duct disorder › cholangitis › acute cholangitis › acute cholecystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
MoxifloxacinPhase 3 (in late-stage trials)
PiperacillinPhase 3 (in late-stage trials)
Sodium ChloridePhase 3 (in late-stage trials)
TazobactamPhase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 72.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified64
PHASE43
PHASE33
PHASE2/PHASE31
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02057679PHASE4COMPLETEDExtended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis
NCT04624841PHASE4UNKNOWNIndocyanine Green to Visualize Critical View of Safety During Laparoscopic Cholecystectomy for Acute Cholecystitis
NCT05709548PHASE4UNKNOWNUse of Indocyanine Green in Acute Cholecystitis
NCT05893511PHASE3RECRUITINGEUS-GBD vs Antibiotics for Patients at High Risk for Cholecystectomy
NCT00447304PHASE3COMPLETEDAcute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy
NCT01625247PHASE3UNKNOWNDrainage is Not Necessary Procedure After Laparoscopic Cholecystectomy Due to Severe Acute Cholecystitis
NCT02212717PHASE2/PHASE3COMPLETEDA Randomized Controlled Trial on EGBD vs PC for Acute Cholecystitis.
NCT02070627PHASE1COMPLETEDNear Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy – Use in Acute Cholecystitis Sub-Study
NCT03643718Not specifiedRECRUITINGWeb-based International Register of Emergency Surgery and Trauma
NCT04813055Not specifiedRECRUITINGProspective Registry Of Therapeutic EndoscopiC ulTrasound
NCT05732480Not specifiedRECRUITINGInfluence of Gut Microbiome in Gallstone Disease
NCT06228027Not specifiedNOT_YET_RECRUITINGExternal Validation os the ACME Scoring System
NCT06287112Not specifiedRECRUITINGPrevention of Acute Cholecystitis With ETGBD
NCT06459323Not specifiedNOT_YET_RECRUITINGthe Outcomes of Laparoscopic Cholecystectomy for Acute Cholecystitis Within and Beyond the First 72 Hours, Does it Differ?!
NCT06820541Not specifiedNOT_YET_RECRUITINGGallbladder Stenting in FC-SEMS
NCT06967597Not specifiedRECRUITINGConservative Versus Proactive Management of Acute Cholecystitis After EUS-guided Transmural Gallbladder Drainage: FUGITIVE Trial (FUGITIVE)
NCT07006298Not specifiedRECRUITINGOne-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis
NCT07161960Not specifiedRECRUITINGEarly Versus Delayed Cholecystectomy After Percutaneous Cholecystostomy in Moderate and Severe Cholecystitis (ESCAPE)
NCT07481760Not specifiedNOT_YET_RECRUITINGAcute Cholecystitis Biliary Complications - ICG
NCT07551375Not specifiedRECRUITINGDiagnostic Value of Deep Learning-Based Rapid MRI in Preoperative Evaluation of Acute Cholecystitis
NCT07552701Not specifiedRECRUITINGUSG-Guided TAPA vs RIFB Block for Postoperative Analgesia in Laparoscopic Cholecystectomy
NCT01548339Not specifiedTERMINATEDLaparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms
NCT01706068Not specifiedUNKNOWNTransient ECG Changes in Patients With Acute Biliary Disease
NCT01942356Not specifiedCOMPLETEDEvaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor
NCT02027402Not specifiedCOMPLETEDEffects of Drainage in Laparoscopic Cholecystectomy
NCT02100358Not specifiedCOMPLETEDFunctional MRC With Eovist for Acute Cholecystitis
NCT02130245Not specifiedUNKNOWNAcute Cholecystitis: Early Versus Delayed Laparoscopic Cholecystectomy; Randomized Prospective Study
NCT02490293Not specifiedCOMPLETEDIs it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?
NCT02796443Not specifiedCOMPLETEDThe Real World of Acute Cholecystitis
NCT03002051Not specifiedCOMPLETEDEUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent
NCT03122054Not specifiedCOMPLETEDEarly Versus Delayed Cholecystectomy
NCT03296280Not specifiedCOMPLETEDEvaluation of Implementation of a National Point-of-Care Ultrasound Training Program
NCT03729882Not specifiedCOMPLETEDPrimary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
NCT03754751Not specifiedCOMPLETEDEnhanced Recovery in Laparoscopic Cholecystectomy
NCT03853408Not specifiedCOMPLETEDShort Term Outcomes of Acute Cholecystitis Managed at a University Hospital
NCT03999645Not specifiedCOMPLETEDIs it Safe to do Laparoscopic Cholecystectomy for Acute Cholecystitis up to Seven Days?
NCT04059601Not specifiedCOMPLETEDMagnetic Resonance Cholangiography and Intraoperative Cholangiography in Acute Cholecystitis
NCT04145869Not specifiedWITHDRAWNFluorescent Cholangiography During Acute Cholecystitis
NCT04156711Not specifiedCOMPLETEDRemote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery
NCT04197908Not specifiedCOMPLETEDEUS-guided Gallbladder Drainage Instead of Laparoscopic Cholecystectomy for Acute Cholecystitis. A Feasibility Study.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
INDOCYANINE GREEN ACID FORM44
AMOXICILLIN41
CEFTOLOZANE41
MOXIFLOXACIN41
REMIMAZOLAM41
CEPHALOSPORIN31
CEPHALOSPORIN C-11

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvarefogenccgwasgwas_studyhgncicd10cmicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctidumls